Projected Changes in Statin and Antihypertensive Therapy Eligibility With the American Heart Association (AHA) PREVENT Cardiovascular Risk Equations
Authors' conclusion
By assigning lower ASCVD risk predictions, application of the PREVENT equations to existing treatment thresholds could reduce eligibility for statin and antihypertensive therapy among 15.8 million US adults.
Study context
- Population
- US adults aged 30 to 79 years, NHANES 2011 to March 2020median age 53
- Participants
- 7,765 adults
- Exposure
- PREVENT equations vs pooled cohort equations (PCEs)
- Outcome
- Differences in predicted 10-year atherosclerotic cardiovascular disease (ASCVD) risk, ACC and AHA risk categorization, eligibility for statin or antihypertensive therapy, and projected MI or stroke
Methodological detailsnationally representative
- Nationally representative
Main finding
As reported in the abstract
- Reclassified to lower American College of Cardiology (ACC)/AHA risk categories with PREVENT
- 53.0% (95% CI, 51.2%-54.8%)
- Reclassified to higher risk categories
- 0.41% (95% CI, 0.25%-0.62%)
- Decrease in US adults receiving or recommended for statin therapy
- 14.3 million (95% CI, 12.6 million-15.9 million)
- Decrease in US adults receiving or recommended for antihypertensive therapy
- 2.62 million (95% CI, 2.02 million-3.21 million)
- Projected additional MI or stroke over 10 years
- 107 000
Observational data: associations, not effects.
Further findings
Eligibility changes by sex and race
- Eligibility changes would affect twice as many men as women and a greater proportion of Black adults than White adults
Original publication
Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations. JAMA. Published 24 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →